2018CPIC指南：基于TPMT和NUDT15基因型的巯基嘌呤剂量_可搜索.pdfVIP

ArticleType:CPICUpdate

basedonTPMTandNUDT15genotypes:2018update

Schmiegelow15.16,JunJ.Yang

Toxicology,UniversityHospital,Tuebingen,Germany

Janeiro,Brazil

Development,Tokyo,Japan

doi:10.1002/cpt.1304

ofSingapore,Singapore

Copenhagen,Denmark

CorrespondingAuthor:

JunYang,Ph.D.

St.JudeChildrensResearchHospital

262DannyThomasPlace

Memphis,TN38105-2794,USA.

Phone:901-595-2517;Fax:901-595-8869

E-mail:jun.yang@

contact@

genetictesting,NUDT15,CPIC

CONFLICTOFINTEREST

Theauthorsdeclarednocompetinginterestsforthiswork.

FUNDING

(R24GM61374)).

ABSTRACT

).

INTRODUCTION

arebeyondthescopeofthisdocument.

FOCUSEDLITERATUREREVIEW

theearlierliterature.

DRUGS:THIOPURINES

Background

GENES:TPMTANDNUDT15

Background

inAsiansandhavebeenfoundinHispanics.

GeneticTestInterpretation

beincluded.

AvailableGeneticTestOptions

Incidentalfindings

theabsenceofthiopurinetreatment(2).

mostofthedosingrecommendationsinTables2and3.

TherapeuticRecommendations

regionsandclinicalpractice.

TPMTpoormetabolizers(Table2)(4,30).

TPMTstatus.

2)(20).

reductionsarestronglyrecommended(32,33).

intermediatemetabolizersremainslimited.

RecommendationsforIncidentalFindings

Notapplicable.

Otherconsiderations

NUDT15geneticvariation.

outcomeswerenotcompromised(4,8,24,25,28).

themedicalrecordforthelifeofthepatient.

arelessclearcomparedtoTPMT.

ACKNOWLEDGEMENTS

theRobertBoschFoundation,Stuttgart,Germany.

Disclaimer

OMISSIONS.

REFERENCES

Suppl1,S35-7(2004).

TherDrugMonit26,186-91(2004).

(3)

288-95(2010).

TPMTvariants.Pharmacogenetics14,407-17(2004).

2293-301(2001).

Pharmacogenomics11,177-88.

PLoSOne6,e29163(2011).

Monit18,328-34(1996).

(2000).

toxicity.NatGenet48,367-73(2016).

(22)PharmGKB.GeneReferenceMaterialsforTPMT.

Leukemia23,557-64(2009).

(1991)